A pair of studies show that Zepbound can help adults with obesity and overweight achieve sustained and meaningful weight loss ...

Eli Lilly ( LLY 2.92%) has been growing its sales at a good clip over the past year. This is partly thanks to Zepbound, a ...

The company’s shares jumped 15% in the wake of the trials which showed the pill, called orforglipron, helped patients with Type 2 diabetes lose weight ... treatments, Zepbound ($1,086) and ...

As the Food and Drug Administration cracks down on compounded versions of popular weight loss drugs Wegovy (semaglutide) and Zepbound (tirzepatide), Americans who rely on these cheaper medications ...

Ryan Rasmussen was determined to lose weight so he would be around to ski and spend time with his wife and children.

Weight loss medications like Wegovy and Zepbound are gaining popularity as millions turn to them for quick results and potential health benefits. While the outcomes can be positive, Consumer ...

In December 2024, the FDA affirmed that the shortage of tirzepatide, marketed as Zepbound for weight loss, had ended, ...

Eli Lilly is suing four telehealth companies selling compounded versions of the pharmaceutical giant's weight loss drug Zepbound and its diabetes treatment Mounjaro, the company's latest attempt ...

Lilly sells tirzepatide as Mounjaro for type 2 diabetes and Zepbound for obesity. In the complaints, Lilly alleges that the telemedicine companies are marketing tirzepatide mixed with substances ...

This is partly thanks to Zepbound, a weight loss medicine that's already generating more than $1 billion in quarterly sales, although it was approved only in late 2023. Zepbound's prospects still ...